Introduction {#s1}
============

Taurine (2-aminoethane sulfonic acid) is very abundant in plasma and mammalian tissues including brain, where it regulates osmolarity, ion channel activity, neuronal growth and metabolism [@pone.0061733-Chepkova1]--[@pone.0061733-Sergeeva1]. It remains controversial whether taurine can be called "neurotransmitter": some but not other studies reported accumulation of taurine in the synaptic vesicles [@pone.0061733-Gundersen1]; [@pone.0061733-Kontro1] and action potential-dependent release [@pone.0061733-Molchanova1]. Taurine concentrations range from 3 to 9 mM in different species and brain regions and may reach 20 mM or higher in intracellular compartments [@pone.0061733-Albrecht1]. Intracellular concentrations of taurine in the brain are about 400 times higher then extracellular [@pone.0061733-Lerma1] due to the high-affinity uptake system [@pone.0061733-Liu1]. Taurine release from different CNS cells is observed under pathophysiological conditions such as hypoosmotic stress, ischemia or acute hyperammonemia, where its interaction with the receptors for inhibitory neurotransmitters GABA and glycine plays a neuroprotective role [@pone.0061733-Albrecht1]. In many brain areas taurine in concentrations below 1 mM activates glycine but not GABA~A~ receptors, except for the ventrobasal thalamus, where it activates α~4~β~2~δ GABA~A~R-type at physiological concentrations (10--100 µM) [@pone.0061733-Jia1]. Mice deficient in taurine show impaired GABAergic inhibition in the striatum [@pone.0061733-Sergeeva2], indicating yet unrecognised role of taurine for the proper GABAergic signalling. If molecular structure of taurine binding site at different glycine receptor types are known [@pone.0061733-Schmieden1]; [@pone.0061733-Sergeeva3], taurine binding site at GABA~A~ receptor was not yet systematically analysed. Efficacy and potency of taurine is so far only known for a few subunit combinations. Taurine acts as a full agonist at α~1~β~3~ and a partial agonist at α~1~β~3~γ~2~ receptors [@pone.0061733-DominguezPerrot1]; at α~4~β~2~δ receptors taurine elicits even greater currents than GABA [@pone.0061733-Jia1] and at α~6~β~2~δ GABA~A~R taurine is a partial agonist, with variable EC~50~s depending on the expression level [@pone.0061733-Hadley1]. The molecular mechanism that determines the efficacy of taurine at GABA~A~Rs is unknown. A comparative analysis of taurine gating of GABA~A~R containing different β subunits was not yet performed. GABA~A~Rs are heteropentameres composed of five subunits. A multitude of subunits can assemble to functional receptors (α~1--6~, β~1--3~, γ~1--3~, δ-, ε-, θ-, π-and ρ~1--3~) [@pone.0061733-Olsen1]. According to the current view GABA~A~Rs are composed of two α, two β and one γ (or δ) subunits aligned γ-β-α-β-α counter-clockwise when viewed from the synaptic cleft [@pone.0061733-Baumann1]. Mutational analysis studies demonstrated that the agonist binding site is located at the α/β interface and the benzodiazepine binding site at the α/γ interface [@pone.0061733-Olsen1]; [@pone.0061733-Farrant1]; [@pone.0061733-Sigel1]. The binding sites for the partial agonists at GABA~A~R are unclear [@pone.0061733-Downing1]. The largest population of GABA~A~Rs in the rat brain has a subunit composition of α~1~β~2~γ~2~, whereas α~2~β~3~γ~2~ and α~3~βγ~2/3~ together constitute the next most prevalent subtypes [@pone.0061733-Ju1]; [@pone.0061733-McKernan1]. Several subunit combinations such as α~5~β~3~γ~2~ [@pone.0061733-Ju1] and α~4/6~β~2/3~δ [@pone.0061733-McKernan1]; [@pone.0061733-Nutt1] are found exclusively extrasynaptically, with the former type expressed in the hypothalamus. Histaminergic neurons from the tuberomamillary nucleus (TMN) of the hypothalamus were selected for the present study as functional and structural features of their GABA~A~ receptors were previously characterised with the α1, α2, α5, β1, β3, γ1, γ2, ε, but not δ subunit- transcripts being regularly detected [@pone.0061733-Sergeeva4]--[@pone.0061733-Yanovsky1]. We compare now the taurine-sensitivity of native GABA~A~R versus selected GABA~A~R compositions recombinantly expressed in *Xenopus* oocytes. As we aimed to compare properties of recombinant GABA~A~R with the native receptors expressed in hypothalamic neurons we restricted the number of investigated subunits and receptor types to those present in TMN neurons [@pone.0061733-Sergeeva6]; [@pone.0061733-Yanovsky1]. We report that incorporation of the γ subunit reduces taurine efficacy. With the help of site-directed mutagenesis we describe structural determinants for the partial agonism of taurine at γ-containing GABA~A~Rs.

Materials and Methods {#s2}
=====================

Electrophysiology in Native Neurons {#s2a}
-----------------------------------

Experiments were conducted according to the Animal Protection Law of the Federal Republic of Germany (Tierschutzgesetz BGBI.I,S.1206, revision 2006) and European Communities Council directive regarding care and use of animals for experimental procedures (86/609/EEC). Approval by the Ethics Committee for this kind of experiment is not necessary in accordance with the Animal Protection Law of the Federal Republic of Germany (§ 8 Abs.1 Tierschutzgesetz). All efforts were made to minimize the number of animals and their suffering. Brain tissue was removed from mice after decapitation by appropriately trained staff with approval of LANUV NRW (Landesamt für Umwelt, Natur und Verbraucherschutz Nordrhein Westfalen, Düsseldorf), permission number 058/91.

Five to eight week old male mice carrying a point mutation on GABA~A~R γ~2~ subunit (γ~2F77I~) further referred as KI (knock-in) mice and their wild type littermates were generated and genotyped as described previously [@pone.0061733-Cope1]. Slice preparation, isolation of histaminergic neurons with the help of papain, whole-cell patch-clamp recordings in voltage clamp mode, fast drug application and single cell RT-PCR procedures was done as previously described [@pone.0061733-Sergeeva5]; [@pone.0061733-Sergeeva6]. Briefly, sterile patch electrodes were filled with the following solution: 140 mM KCl, 2 mM MgCl~2~, 0.5 mM CaCl~2~, 5 mM EGTA, and 10 mM HEPES/KOH (pH 7.2). After establishment of the whole-cell configuration (Vh = −50 mV), an acutely isolated cell was lifted into the major chute of the application system, where it was continuously perfused with the sterile control bath solution. The substances were applied through a glass capillary 0.08 mm in diameter. All solutions flowed continuously, gravity-driven, at the same speed and lateral movements of the capillaries exposed a cell either to control- or test-solutions. The kinetics of solution exchange at the open electrode tip were characterized by an exponential rise time constant of 7 ms, whereas the maximal GABA-evoked responses reached their maximum up to 2 times slower; thus peak responses represented the sum of activation, desensitization and delay of solution exchange around the large (15--25 µm) neurons (see Schubring et al [@pone.0061733-Schubring1]). For the comparison of apparent desensitization kinetics between zinc sensitive and zinc resistant neurons, only cells with a rise time constant below 10 ms were considered. Experiments were conducted and analyzed with commercially available software (TIDA for Windows, HEKA, Lambrecht, Germany). Fitting of concentration - response data points was done as previously described [@pone.0061733-Sergeeva4]; [@pone.0061733-Sergeeva5]. Post-hoc identification of recorded TMN neurons and GABA~A~R analysis was done with single cell RT-PCR according to the previously published protocols [@pone.0061733-Sergeeva6]; [@pone.0061733-Yanovsky1]. Real-time RT - PCR was used for the semiquantitative analysis of γ~2~ subunit expression in TMN (relative to the β -actin endogenous control according to the "2^−ΔΔCt^ "(ΔFold) method as in [@pone.0061733-Sergeeva6]. After the final cycle the PCR were subjected to a heat dissociation protocol (PE Biosystems 5700 software). Each PCR product showed a single peak in the denaturation curve. Standard curves were obtained with the sequential dilution of one cDNA sample (from KI mouse \#1). From these curves the linear regression coefficient (r = −0.99) and efficiency (E = 1.8) for the β --actin and γ~2~ subunit -- cDNA amplification (r = −0.98, E = 1.9) were calculated, where E = 10^\[−1/slope\]^. Expression levels of the γ~2~-subunit in each sample are normalized to the sample with minimal expression (for this sample: ΔΔC = 0, 2^−ΔΔCt = ^1). The following primers were used: up: 5′-tat gtD aac agc att ggW ccW gt -3′ and lo: 5′-acc atc att cca aat tct cag cat-3′. The size of the PCR product (234 b.p.) was verified by electrophoresis in 2% agarose gel, whereas its identity with the known mouse γ~2~-subunit cDNA (M86572, Genbank) was confirmed by sequencing.

Expression of Recombinant GABA~A~ Receptors and Electrophysiology in Xenopus Oocytes {#s2b}
------------------------------------------------------------------------------------

GABA~A~R subunit cDNAs were obtained as follows: rat α~1~ and β~1~ cDNAs were prepared using standard molecular biology procedures. Mouse γ~2L~, α~2~, and human β~3~ and δ cDNA were obtained from RZPD (Berlin, Germany). Chimeric γ~2(δ\ 74--79)~ was generated using overlap extension PCR [@pone.0061733-Ho1] with the following primer pairs for the exchanged area: fw-γ~2(δ\ 74--79)~ '5-atg gaa tat aca atg acg gtg ttc ctg cac cag agc tgg cgg gac aga cgt ttg aaa ttt aac-3′ and rev- γ~2(δ\ 74--79)~ '5-gtt aaa ttt caa acg tct gtc ccg cca gct ctg gtg cag gaa cac cgt cat tgt ata ttc cat-3′. All cDNAs were subcloned into pSGEM (courtesy of M. Hollmann, Bochum, Germany). Plasmids were linearized with PacI restriction endonuclease and corresponding cRNA was synthesized using the AmpliCap T7 high-yield message marker kit (Epicentre, Madison, WI), following the manufacturers protocol. 5 to 15 ng of the mixture of cRNAs with a ratio of 10∶1:10 for αβγ/δ was injected into every oocyte to prevent subpopulations of β homomultimeric GABA~A~R [@pone.0061733-Saras1]. Two to six days after injection of cRNA, oocytes were screened for receptor expression by two-electrode voltage-clamp recording. Electrodes were made using a Kopf vertical micropipette puller and filled with 3 M potassium chloride, giving resistances of 0.1--0.5 MΩ. Eggs were placed in an oocyte chamber and superfused with Frog-Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl~2~, 10 mM Hepes, pH 7.2). Current signals were recorded with a two-electrode voltage - clamp amplifier (TURBO TEC-03, npi, Tamm, Germany) and pCLAMP software (Axon Instruments, Union City, CA) or CellWorks (npi, Tamm, Germany) depending on the setup used. The membrane potential was clamped at −40 to −60 mV. All experiments were performed at room temperature. Complete concentration - response curves for GABA and taurine were recorded on the same oocyte. These agonists of GABA~A~R were dissolved in Frog-Ringer and applied in a volume of 200 µl into the entrance tube of the recording chamber, totally exchanging the bath solution within a second. Currents were analyzed using pCLAMP 10 software. Dataset was processed in Excel (Microsoft Corporation, Redmond, WA). Curve fitting by the 3 parameter Hill equation and statistics (t - test) was done using SigmaPlot V8.0 (Systat Software, San Jose, CA). Taurine efficacy was determined by the maximum of the taurine concentration - response curve calculated by the 3 parameter Hill equation in relation to the maximum current of the GABA concentration - response curve. Proper γ subunit integration into the GABA~A~R was analysed using zinc. Ternary αβγ GABA~A~Rs are insensitive to low micromolar concentrations of zinc, whereas binary αβ receptors are inhibited by those concentrations [@pone.0061733-Draguhn1] ([Figure S1](#pone.0061733.s001){ref-type="supplementary-material"}). Delta (δ) - containing GABA~A~R have intermediate zinc sensitivities [@pone.0061733-Nagaya1], therefore our criterion for δ subunit integration was the modulation of GABA - evoked currents by tracazolate ([Figure S2](#pone.0061733.s002){ref-type="supplementary-material"}). In accordance with Thompson et al. [@pone.0061733-Thompson1] we found that tracazolate potentiates ternary δ - containing GABA~A~R to a larger extent than the corresponding binary α~x~β~x~ receptors.

Drugs and Statistical Analysis {#s2c}
------------------------------

Gabazine (SR 95531) and tracazolate were obtained from Tocris-Biotrend (Köln, Germany). All other chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany). Drugs were diluted and stored as recommended. Statistical analysis was performed with the non - parametrical Mann - Whitney U-test if not indicated otherwise. Significance level was set at p\<0.05. Data are presented as mean ± standard error of the mean (SEM).

Results {#s3}
=======

Taurine Efficacy and Potency at GABA~A~ Receptors Composed of α and β Subunits {#s3a}
------------------------------------------------------------------------------

In accordance with the study performed in HEK 293 cells by Dominguez-Perrot et al. [@pone.0061733-DominguezPerrot1] recombinant GABA~A~R composed of α~1~- and β~3~ -subunits in our study responded to GABA and to taurine with maximal currents of similar amplitude ([Table 1](#pone-0061733-t001){ref-type="table"}). At receptors containing the β~1~-subunit taurine demonstrated super-agonism, eliciting maximal responses nearly two times larger than the maximal GABA responses ([Table 1](#pone-0061733-t001){ref-type="table"}). When the α~1~-subunit was replaced by the α~2~-subunit GABA and taurine potencies were reduced at β~1~-containing receptors whereas taurine potency at β~3~-containing receptors was not affected. Taurine efficacy was independent of the α-subunit type and was determined by the β-subunit type.

10.1371/journal.pone.0061733.t001

###### GABA- and taurine- gating of different GABA~A~ receptor types recombinantly expressed in Xenopus oocytes.

![](pone.0061733.t001){#pone-0061733-t001-1}

                                  GABA           Taurine                                                     
  -------------------------- --------------- --------------- --------------- --------------- --------------- -------
  **α~1~β~1~**                **1.82±0.13**    **8.0±0.8**    **2.26±0.27**   **0.71±0.07**   **59.3±18.8**     4
  α~1~β~1~δ                     1.85±0.10        8.5±1.8       2.75±0.05\*      0.60±0.02     162.6±33.4\*      5
  α~1~β~1~γ~2~                  1.82±0.16       10.0±1.1       0.81±0.03\*     1.20±0.04\*      17.6±2.18       4
  α~1~β~1~γ~2~ ~(δ74--79)~     1.38±0.10\*     13.2±1.6\*      2.7±0.30\*      0.48±0.02\*    433.4±94.8\*      7
  α~1~β~1~γ~2F77I~              1.60±0.13      36.2±6.7\*      0.53±0.10\*      0.91±0.09       68.6±13.9       5
  **α~1~β~3~**                **1.92±0.21**    **7.8±0.8**    **1.06±0.06**   **0.96±0.09**   **26.1±9.5**      5
  α~1~β~3~δ                    1.44±0.09\*      21.4±8.1       0.74±0.04\*      1.09±0.08       45.3±10.5       6
  α~1~β~3~γ~2~                  1.68±0.15      16.7±2.3\*      0.63±0.09\*     1.30±0.13\*     86.3±16.5\*      5
  α~1~β~3~γ~2\ (δ74--79)~      1.34±0.03\*    48.4±14.2\*\*    0.44±0.07\*      0.94±0.09      92.9±16.3\*      5
  α~1~β~3~γ~2\ F77I~            1.58±0.13      66.4±86.3\*     ∼0.21±0.04         n.p.            n.p.          5
  **α~2~β~1~**                **1.86±0.19**   **18.0±2.1**    **1.80±0.14**   **1.12±0.16**   **81.8±24.9**     7
  α~2~β~1~δ                     1.72±0.11       19.1±1.4        1.94±0.11       1.02±0.09       67.8±15.9       6
  α~2~β~1~γ~1~                 1.35±0.10\*     87.1±7.1\*      0.64±0.03\*      1.22±0.30      107.2±25.8       4
  α~2~β~1~γ~2~                 1.37±0.08\*     71.2±12.5\*    0.65±0.05\*\*     1.06±0.06      120.3±26.0       5
  α~2~β~1~γ~2\ (δ74--79)~       1.88±0.04       15.1±0.4        1.43±0.06       0.98±0.07       40.5±6.9        7
  α~2~β~1~γ~2\ F77I~            1.68±0.06      58.2±3.9\*     0.49±0.02\*\*     1.29±0.02       76.1±3.9        5
  **α~2~β~3~**                **1.48±0.21**   **12.9±6.5**    **1.03±0.04**   **1.07±0.08**   **24.5±11.2**   **4**
  α~2~β~3~δ                     1.47±0.06       13.5±1.0        1.10±0.03      1.29±0.03\*      35.4±2.0        7
  α~2~β~3~γ~1~                  1.45±0.05      93.8±12.2\*     ∼0.44±0.04         n.p.            n.p.          4
  α~2~β~3~γ~2~                 2.12±0.01\*      18.7±0.9       0.87±0.03\*      1.14±0.11       51.2±19.8       4
  α~2~β~3~γ~2~ ~(δ74--79)~      1.47±0.05      42.8±5.8\*      0.51±0.03\*      1.11±0.07     137.1±26.2\*      5
  α~2~β~3~γ~2F77I~              1.65±0.13      68.8±7.4\*      0.36±0.02\*      1.29±0.12     174.4±28.7\*      5

GABA I ~max~ = 1; Responses to different taurine concentrations relative to I GABA max were fitted with a logistic Hill equation as shown in [Fig. 1:](#pone-0061733-g001){ref-type="fig"} EC~50~, nHill and maximal efficacy (relative to GABA), obtained from this curve-fit analysis are provided for each receptor type. Exceptions are marked with ∼ (in these two cases, the curve-fit failed due to the large deviation from mean of experimental values. Mean relative response amplitude (to 0.6 M taurine) is given). Values represent mean ± SEM. n.p. = not predictable. All values were compared to those seen in the corresponding binary (α~x~β~x~) receptor type (fat); significant difference is indicated (\*p\<0.05, \*\*p\<0.01, non - parametrical Mann - Whitney U-test).

Presence of γ~2~-subunit Reduces Taurine Efficacy {#s3b}
-------------------------------------------------

When co-assembled with the α- and β-subunits the γ~2L~ subunit negatively affected taurine efficacy in all receptor types. At α~2~β~3~γ~2L~ taurine efficacy (0.87) showed the slightest but significant deviation in efficacy reduction compared to the binary α~2~β~3~ receptors ([Table 1](#pone-0061733-t001){ref-type="table"}, [Fig. 1](#pone-0061733-g001){ref-type="fig"}). After integration of the γ~2L~ or γ~1~ subunit into β~1~-containing receptors, the efficacy of taurine was reduced to about 1/3 of the binary α~x~β~1~ receptor and taurine could be called a "partial agonist". Previous studies have shown that the putative assembly signals, the residues determining selective co-assemblies of α-β or α-γ~2~, in GABA~A~Rs [@pone.0061733-Bollan1] as well as in nicotinic acetylcholine receptors [@pone.0061733-Kreienkamp1], are adjacent to, or identical to the residues that actually form the ligand-binding site. Thus, the α~1~ residues 56--67, in particular glutamine 67 (α~1Q67~), are important for the assembly with the β~3~ subunit and are involved in the formation of the low affinity GABA-binding site [@pone.0061733-Bollan1]; [@pone.0061733-Taylor1]. The γ~2~A assembly signal (MEYTIDIFFAQTW) [@pone.0061733-Bollan1] which interacts with the α subunit includes phenylalanine at position 77 (F77). This residue plays an important role for the zolpidem modulation of γ~2~-containing GABA~A~R [@pone.0061733-Wingrove1].

![Comparison of taurine- and GABA-evoked maximal currents recorded from binary α~x~β~x~ (A) or ternary α~x~β~x~γ~2L~ (B) GABA~A~ receptors.\
Note that gating by taurine of γ~2~ subunit containing GABA~A~ receptors is significantly less efficacious compared to the corresponding binary receptors. Representative current traces (comparison of taurine (600 mM) - and GABA (0.1--1 mM) -evoked maximal currents at different receptor subtypes) are shown at the left. Scale markers represent 0.1 µA vertically and 20 s horizontally for all figures with oocyte recordings. Right: averaged concentration - response curves. Concentration of agonist (filled symbols for GABA -, open symbols for taurine - responses) is plotted versus normalized response amplitudes. Each individual measurement was first normalized to the observed maximal GABA - current amplitude and subsequently averaged. Number of investigated oocytes, Hill coefficients (nHill) and concentrations evoking a half - maximal response (EC~50~) are presented in [Table 1](#pone-0061733-t001){ref-type="table"}.](pone.0061733.g001){#pone-0061733-g001}

Role of Zolpidem Binding Site for the GABA~A~R Gating by Taurine {#s3c}
----------------------------------------------------------------

The mutation of phenylalanine to isoleucine at position 77 of GABA~A~R γ~2~ subunit (γ~2F77I~) leads to the loss of zolpidem-modulation of GABA-responses in recombinant and native receptors [@pone.0061733-Cope1]; [@pone.0061733-Wingrove1]. This is the only residue, which is different between the γ~2~ and the γ~1~ subunit within the putative assembly signal γ~2~A (see above). As taurine was significantly less efficient at α~2~β~3~γ~1~- than at α~2~β~3~γ~2~- receptors ([Table 1](#pone-0061733-t001){ref-type="table"}) we generated a mutated γ~2F77I~ subunit using overlap extension PCR techniques [@pone.0061733-Ho1]. Proper incorporation of γ~2F77I~ into GABA~A~R was verified by zinc-resistance ([Figure S1](#pone.0061733.s001){ref-type="supplementary-material"}). In all investigated receptor types taurine efficacy was significantly reduced at mutated compared to the corresponding wild type receptors: p\<0.05 for α~1~β~1~γ~7F77I~; p\<0.01 for α~2~β~1~γ~2F77I~; p\<0.001 for α~2~β~3~γ~2F77I~ ([Table 1](#pone-0061733-t001){ref-type="table"}, [Fig. 2](#pone-0061733-g002){ref-type="fig"}). As previous studies examining macroscopic (whole-cell currents) and microscopic (single-channel currents) kinetics of recombinant GABA~A~R with a mutation within the GABA-binding site came to the conclusion that the reduction in agonist potency (e.g. a 70-fold increase in EC~50~ for GABA after mutation β~2~-R207C) may be accompanied by the apparent reduction (by half) of the relative efficacy of a partial agonist (e.g. piperidine-4-sulfonic acid, P4S) under the slow, but not under the fast solution exchange conditions [@pone.0061733-Wagner1]. In order to control for this possibility we performed a correlation analysis between the relative potency of taurine (EC~50~ taurine/EC~50~ GABA) versus relative efficacy of taurine for all individual measurements from γ~7F77I~ --containing and corresponding WT receptors. There was no significant correlation (Pearson coefficient: −0.07, p = 0.75). Taurine was 1965±219 times (n = 15) and 1692±154 times (n = 11) less potent than GABA in KI and WT receptors, respectively (p = 0.8), but its relative efficacy was significantly lower in KI receptors (45.6±3.7% vs 74.6±3.7%, respectively, p = 0.0002).

![Mutation γ~2F77I~ reduces taurine efficacy at recombinant GABA~A~ receptors.\
(**A**) Representative current traces show responses to the maximal GABA and taurine concentrations at different receptor types. For two representative receptor types (marked with symbols) concentration-response plots for GABA (filled symbols) and taurine (open symbols) are shown in (**B**) and (**C**). Data obtained in corresponding wild type receptors (γ~2~ instead of γ~2F77I~) are plotted in red.](pone.0061733.g002){#pone-0061733-g002}

GABA~A~ Receptors in Zinc-resistant Neurons from Mutant γ~2F77I~ Mice show Reduced Taurine Gating {#s3d}
-------------------------------------------------------------------------------------------------

Acutely isolated mouse TMN neurons responded to GABA with EC~50~s around 15 µM. There was no difference in GABA-sensitivity between γ~2F77I~ mice and their WT littermates. All data presented in the manuscript are obtained from neurons expressing histidine decarboxylase (cell identification with single-cell RT-PCR). In contrast to the rat [@pone.0061733-Sergeeva4], where GABA~A~Rs are "zinc-resistant" in all TMN neurons, about 30% of mouse TMN neurons are zinc-sensitive. No difference in the occurrence of zinc- sensitivity was found between γ~2F77I~ (knock-in, KI) mice and their WT littermates (27.7% and 27% of cells, respectively). GABA EC~15~ responses were inhibited by 30 µM of ZnCl~2~ in zinc-sensitive cells to 28.2±5.3% of control and by 10 µM to 52.1±5.9% of control (pooled data from 3 WT and 5 KI neurons, where a complete analysis of GABA~A~R expression with single-cell RT-PCR was successfully done, [Fig. 3](#pone-0061733-g003){ref-type="fig"}). In zinc-resistant cells, where 10 µM of zinc did not affect GABA-responses, inhibition by 30 µM zinc amounted to 74.1±2.2% of control (significantly different from "zinc-sensitive" cells; p\<0.01). The apparent macroscopic desensitization of current responses to saturating GABA concentration (plateau/peak ratio at the end of a 2s-application period) amounted to 73.3±3.3% (n = 5) vs 67.6±3.7% (n = 10), in zinc-sensitive and zinc-resistant cells respectively (the difference is not significant). In 25% of the zinc-sensitive cells mRNAs encoding for γ subunits were not detected, whereas in the same cells α- and β-subunit transcripts were present. Two different γ subunits were never found coexpressed in zinc-sensitive neurons, whereas 48% of zinc-resistant cells coexpressed γ~1~ and γ~2~ subunits (p\<0.05, Fisher's test). All zinc-resistant cells (n = 21) expressed either γ~1~ (57%) or γ~2~ (90.5%) subunit or both. The detection frequency of any of the GABA~A~R subunits did not differ between 11 WT and 18 KI neurons (% of positive cells: WT vs KI): α~1~ in 18% vs 28%, α~2~ in 100% vs 94%, α~5~ in 18% vs 17%, β~1~ in 18% vs 44%, β~2~ in 9% vs 17%, β~3~ in 91% vs 78%, γ~1~ in 36% vs 50% and γ~2~ in 82% vs 83%. None of the cells expressed a detectable amount of γ~3~ subunit transcripts. Semiquantitative real-time PCR analysis of γ~2~ subunit expression revealed no difference in mRNA levels between TMN of γ~2F77I~ KI mice (n = 5) and their WT littermates (n = 5): 1.5±0.1 vs 1.5±0.2 (p = 0.83). In WT mice taurine was more effective (p\<0.05) in "zinc-sensitive" cells compared to "zinc-resistant" ones ([Fig. 3B and C](#pone-0061733-g003){ref-type="fig"}). In "zinc resistant cells" taurine was significantly more efficient in WT (72±2.4% of maximal GABA-currents, n = 10) compared to KI mice (53±2%, n = 14; [Fig. 4A and B](#pone-0061733-g004){ref-type="fig"}). Neither taurine potency (13±1 mM vs. 19.4±1.3 mM) nor slope functions of dose-response curves (nHill 1.7±2 vs. 1.74±0.14) differed between WT and KI neurons. The GlyR-mediated component of taurine-responses was subtracted from each response-amplitude (remaining component after co-application of taurine and gabazine 20 µM, [Fig. 4C](#pone-0061733-g004){ref-type="fig"}).

![Zinc-sensitive TMN neurons show similar efficacies for GABA and taurine.\
(**A**) Zinc-inhibition of GABA-evoked currents in two representative neurons. Note that these neurons respond differently to ZnCl~2~ 10 µM. Block of the GABA-response by this concentration served as a criterion for the selection of "zinc-sensitive" neurons. (**B**) Photographs of two neurons and gels illustrating single-cell RT-PCR analysis of γ-subunit (γ1--γ3) expression. Note the lack of a detectable amount of γ-subunit transcripts in zinc-sensitive cell (\#2). (**C**) Superimposed responses to different concentrations of taurine in comparison to the maximal GABA response recorded in one zinc-sensitive neuron. (**D**) Averaged concentration - response plots for the two neuronal groups. Significant difference between individual data points is indicated: \* = p\<0.05. The maximal taurine-evoked currents represented 100±5% (filled squares, EC~50~ = 12.6±0.6 mM, n = 5) vs 74±2% (open squares, EC~50~ = 14.9±0.9 mM, n = 6) of maximal GABA-evoked currents.](pone.0061733.g003){#pone-0061733-g003}

![Gating of native GABA~A~ receptors by taurine is impaired by the mutation γ~2F77I~.\
(**A**) Whole-cell voltage-clamp recordings (V~h~ = −50 mV) from adult WT or KI mouse TMN neurons isolated from hypothalamic slices. Taurine evokes maximal responses (at 50 and 100 mM) which are comparable in amplitude to the maximal GABA (0.5 mM)-evoked currents in wild-type (WT) mouse but represents only half of the GABA-response in the knock-in (KI) γ~2F77I~ mouse. (**B**) Averaged concentration - response curves obtained from 10 WT and 14 KI neurons. Significant difference between individual data points is indicated: \* p\<0.05; \*\*\* p\<0.005. (**C**) GABA~A~R- versus GlyR-involvement in taurine-responses was tested by the co-application of taurine with gabazine (gz, GABA~A~R antagonist). Amplitude of the remaining response was subtracted in each neuron from the control taurine response, to construct the concentration - response curves in (B).](pone.0061733.g004){#pone-0061733-g004}

Super-agonistic Properties of Taurine at α~x~β~1~δ-receptors can be Transferred to the α~x~β~1~γ~2L~ Receptors by Introducing into the γ~2L~ Subunit the δ-motif: MTVFLH {#s3e}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This and previous studies show that δ-containing receptors are more potently and efficiently gated by taurine than γ-containing receptors. The molecular determinants for high sensitivity to taurine are unknown. We exchanged the γ~2~ motif around phenylalanine 77 which we found to be responsible for the reduced efficacy of taurine with the corresponding motif of the δ subunit ([Fig. 5](#pone-0061733-g005){ref-type="fig"}). The resulting chimeric receptors α~x~β~1~γ~2(δ74--79)~ displayed superagonistic properties of taurine, which did not differ significantly from the α~x~β~1~δ receptors ([Table 1](#pone-0061733-t001){ref-type="table"}, [Fig. 6](#pone-0061733-g006){ref-type="fig"}). Interestingly, co-assembly of the chimeric γ~2~ subunit with α~x~ and β~3~ subunits did not render taurine agonism superior to GABA ([Table 1](#pone-0061733-t001){ref-type="table"}). Chimeric α~2~β~3~γ~2(δ74--79)~ receptors were insensitive to zolpidem, like α~2~β~3~γ~2F77I~ or α~2~β~1~γ~1~ receptors ([Figure S3](#pone.0061733.s003){ref-type="supplementary-material"}). When GABA (at EC~10~) was co-applied with 1 µM zolpidem, the resulting currents represented 97±7% of control (n = 5). At wild type α~2~β~3~γ~2~ receptors the same concentration of zolpidem increased control GABA-response to 430±70% of control (n = 5). Thus, zolpidem insensitivity could be transferred from δ to γ~2~ through the motif MTVFLH.

![Sequence alignment of GABA~A~ receptor subunits between amino acids 58 and 92 (γ~2~ mouse numbering).\
Underlined is a putative assembly signal conserved in different GABA~A~ receptor subunits (36)). Note no difference between all three β- subunits in the putative assembly signal: MDYTLTMYFQQ_W with the exception for the position 81 (different residues are indicated in different colour). Interestingly, these coloured β subunit-specific residues were shown previously to affect stabilization of a homomeric assembly (45). Fat letters show δ: MTVFLH and γ~2~: IDIFFA motifs which were exchanged in the chimeric γ~2(δ74--79)~ subunit. Orange field indicates location of γ~2F77~ site involved in zolpidem binding as well as homologous or same residues at other GABA~A~R subunits.](pone.0061733.g005){#pone-0061733-g005}

![Chimeric α~x~β~1~γ~2(δ74--79)~ receptors show superagonistic properties of taurine.\
(**A and B)** Representative current traces (comparison of taurine (600 mM) - and GABA (0.3--3 mM) - evoked maximal currents) are shown for different receptor types. (**A**) Concentration - response curves for the β~1~ -containing receptors. Concentrations of agonist are plotted versus current amplitudes normalized on maximal GABA response (filled symbols for GABA -, open symbols for taurine - responses). Red curves are given for comparison with γ~2~ (WT) - containing receptors. Note the dramatic increase in taurine efficacy over GABA in chimeric β~1~ - containing GABA~A~R, which renders them similarity with the α~2~β~1~δ receptors.](pone.0061733.g006){#pone-0061733-g006}

Discussion {#s4}
==========

We demonstrate that taurine gating depends on the type of β subunit and is negatively affected by the γ subunit of the GABA~A~R. The mutation γ~2F77I~ which makes the GABA~A~R zolpidem-insensitive reduces the efficacy of taurine-gating in recombinant and native GABA~A~ receptors. Substitution of the γ~2~ subunit motif around phenylalanine 77 (mouse γ~2~ subunit numbering) with the corresponding δ subunit motif (MTVFLH) results in a receptor with superagonistic properties of taurine in β~1~- but not in β~3~- containing receptors.

Our results obtained on recombinant GABA~A~R expressed in Xenopus oocytes are in line with a previous report on decreased efficacy and potency of taurine at ternary α~1~β~3~γ~2~ receptors compared to binary α~1~β~3~ receptors expressed in HEK293 cells [@pone.0061733-DominguezPerrot1]. This decrease in efficacy was accompanied by decreased taurine potency at α~1~β~3~γ~2~ and α~2~β~3~γ~2~ receptors ([Table 1](#pone-0061733-t001){ref-type="table"}; present study and [@pone.0061733-DominguezPerrot1]). Interestingly, β~1~-coassembly with the γ~2~ subunit resulted in a reduction of taurine efficacy and potency in α~2~- but an increased potency in α~1~-containing pentamers in our study. We are aware of the technical limitations in our measurements of maximal efficacies and potencies of GABA~A~R agonists due to the slow speed of the solution exchange around an oocyte. Apparent efficacies and potencies were calculated from the peak responses which represent the sum of different processes such as fast kinetics of receptor activation and desensitization and the slow concentration ramp. Theoretical predictions formulated in a study by Wagner et al [@pone.0061733-Wagner1] are the following: i) the true maximal efficacy or open probability is underestimated in experiments on oocytes as desensitization during the agonist concentration ramp blunts the peak amplitude of the response; ii) the degree of this blunting depends on ligand affinity, such that high affinity ligands reach higher effective concentrations sooner during the agonist concentration ramp than do low affinity ligands. Although absolute efficacy and potency values can only be obtained from experiments recording single channel activity, our results from Xenopus oocytes are in line with those from HEK293 cells [@pone.0061733-DominguezPerrot1] and native neurons (present study) where a much faster solution exchange around smaller cells was achieved. Combining patch-clamp recordings from hypothalamic neurons with single-cell RT-PCR we observed the same structure-function relation for taurine gating of native GABA~A~R as seen in Xenopus oocytes. Thirty percent of mouse histaminergic neurons expressed GABA~A~Rs with high zinc sensitivity indicating the prevalence of binary (α~x~β~x~) receptors over ternary (α~x~β~x~γ~x~) in these cells. The functionality of such receptors was demonstrated by Gunther et al. [@pone.0061733-Gunther1] in γ2 - subunit knockout mice. Taurine efficacy was comparable to GABA in zinc-sensitive cells, whereas taurine was less efficient than GABA in zinc-resistant cells, in keeping with the findings on recombinant γ-containing receptors expressed in *Xenopus* oocytes ([Table 1](#pone-0061733-t001){ref-type="table"}), where taurine efficacy varied between 60--70% (α~1~β~3~γ~2,~ α~2~β~1~γ~1,~ α~2~β~1~γ~2~) and 80--90% (α~1~β~1~γ~2~, α~1~β~2~γ~2,~ α~2~β~3~γ~2~) of maximal GABA-responses. Note that in TMN neurons, which variably express 9 subunits of GABA~A~R [@pone.0061733-Sergeeva6], all aforementioned GABA~A~R types are likely occurring. The potency of taurine was not different between zinc-sensitive and zinc-resistant neurons, indicating that α~1~- and α~2~-containing GABA~A~R-populations, which show different changes in taurine potency upon co-assembly with the γ subunit (see above), may both contribute to the TMN pharmacology.

Receptors lacking a benzodiazepine (BZ) -binding site, such as α~1/2~β~1~, and α~1/2~β~1~δ, are better gated by taurine than by GABA ([Table 1](#pone-0061733-t001){ref-type="table"}, [Fig. 1](#pone-0061733-g001){ref-type="fig"}). Our observation that taurine gating of β~3~-containing receptors with the same stoichiometry was weaker compared to β~1~-containing receptors could be explained by the presence of a low - affinity binding site for BZ at β~2/3~ but not at β~1~ receptors [@pone.0061733-Walters1]. The mutation γ~2F77I~ which abolished zolpidem - potentiation did not rescue taurine gating. In contrast, taurine efficacy significantly dropped in this mutation, resembling now the taurine efficacy at the equivalent γ~1~ - containing receptors, which are poorly potentiated by a variety of BZ - site ligands [@pone.0061733-Wingrove1] and naturally carry isoleucine at the position 77. We conclude that steric intersubunit - interactions (see below), rather than the BZ - binding site per se, play a decisive role for taurine or GABA gating as well as for the modulatory action of BZ.

In line with the data obtained on recombinant receptors containing the mutant γ~2F77I~ subunit, taurine efficacy was reduced in zinc - resistant native neurons from KI (γ~2F77I~) mice from 72% to 54% of maximal GABA efficacy. This efficacy drop corresponds very well to the values obtained from recombinant α~2~β~1~γ~2~ receptors (70% WT vs. 50% in α~2~β~1~γ~2F77I~ ) and supports our previous conclusion that the α~2~β~1~γ~2~ receptor type plays a dominant role for the pharmacology of TMN neurons [@pone.0061733-Sergeeva6]; [@pone.0061733-Yanovsky1]. Thus the mutation γ~2F77I~ modified taurine - efficacy at the γ~2~ - containing GABA~A~Rs. The (patho)physiological conditions for the gating of these receptors by taurine are unknown. The normal extracellular concentration of taurine is \>20 times below their activation threshold. The expression of the α~4~ and δ subunits increases in the hippocampus of γ~2F77I~ KI mice, indicating that δ - containing receptors might be up -regulated as compensatory response for the impaired taurine efficacy at γ~2~ - containing receptors. This may be a reason for the lack of behavioural abnormalities in these mice compared to WT littermates [@pone.0061733-Cope1]; [@pone.0061733-Nagaya1]. Jia et al. [@pone.0061733-Jia1] reported that, at extrasynaptic receptors of the α~4~β~2~δ-type, taurine shows agonistic properties superior to GABA and controls the excitability of mouse ventrobasal thalamic neurons. Jia et al. found a big difference in taurine sensitivity between recombinant α~4~β~2~δ receptors (threshold concentration 300 µM, EC~50~ = 7.5 mM) and native extrasynaptic receptors of possibly the same subunit composition (threshold concentration 10 µM, potency is not determined). In our study taurine showed higher potency at neuronal receptors (EC~50~ = 13--19 mM) compared to the corresponding recombinant α~2~β~1~γ~2~-receptors (EC~50~ = 120 mM) with threshold concentrations just above 1 mM. This disparity may result from the absence of GABA~A~R - associated proteins or yet unknown intracellular modulators in recombinant systems [@pone.0061733-Jia1]. The exceptionally high potency and efficacy of taurine at α~4~β~2~δ receptors reported by Jia et al [@pone.0061733-Jia1] together with the partial agonism of taurine at α~6~β~2~δ receptors [@pone.0061733-Hadley1] support our observation that the type of α subunit influences taurine binding or the transduction to receptor gating. Neither α~1~β~x~δ nor α~2~β~x~δ receptors in our study showed higher sensitivities to GABA when compared to the corresponding α~x~β~x~ receptors. This is in line with previous studies [@pone.0061733-Baur1]; [@pone.0061733-Kaur1] where incorporation of the δ subunit was verified by concatenation. We applied tracazolate [@pone.0061733-Thompson1] at the end of each experiment to confirm the presence of a δ subunit in functional receptors. All data presented here are obtained from oocytes with different modulation of ternary versus binary receptors in parallel experiments. We cannot rule out the possibility of a sub-population of α~x~β~x~ receptors along with α~x~β~x~δ, which we tried to prevent by injection of 10∶1:10 cRNA ratios. Furthermore, significantly different parameters derived from the agonist concentration - response relationship ([Table 1](#pone-0061733-t001){ref-type="table"}) indicates a prevalence of α~x~β~x~δ receptor types. We compared taurine agonism between the restricted number of GABA~A~R types expressed in histaminergic neurons and used δ- containing receptors (which are not expressed in TMN) only for the comparison with chimeric receptors, composed of the γ~2~ subunit with a δ-motif (MTVFLH). Structural determinants for super- and partial- agonism of taurine at δ-containing receptors await further characterisation.

The differences between β~1~ and β~3~ subunits seen in our study may rely on a number of subunit - specific residues involved in the stabilisation of receptor assembly. Bracamontes and Steinbach [@pone.0061733-Bracamontes1] described a number of β~3~ - specific residues allowing the formation of functional homomultimeric receptors. Some of them are located near or within the assembly signal, e.g. tyrosine at the position 81 (see [Fig. 5](#pone-0061733-g005){ref-type="fig"}, present study). Others are at remote places and unlikely involved in gating or agonist binding; they may play a role in the stabilization of different receptor conformations. Steric intersubunit interactions in heteromeric β~1~-containing receptors may support the stable transition from the closed to the open state after taurine binding at the α~x~β~1~δ, α~x~β~1~γ~2(δ74--79)~ and α~x~β~1~ receptor, with taurine acting as a superagonist. In contrast, at β~3~ - containing receptors taurine acts as a partial agonist compared to the analogous receptor types.

Our study reveals the importance of the γ~2~ motif around phenylalanine 77 for the reduction of taurine efficacy at γ - containing receptors and shows that all three subunit types (α~,~β~,~γ) in the GABA~A~ receptor can influence taurine agonism. Recent studies showed that the partiality of ligand agonism is pre - determined by the earliest step of agonist binding [@pone.0061733-Lape1]; [@pone.0061733-Mukhtasimova1]. According to models suggested by these studies, partial agonist-binding generates an unstable conformational change, leading to receptor-flipping between closed and opened states [@pone.0061733-Lape1]. Thus, the difference between taurine - and GABA - gating of GABA~A~R shown in this study indicates either a different but overlapping location of their binding sites or different transduction mechanisms at different receptor types.

By revealing structural demands for high efficacy GABA~A~R gating by taurine our study has broad physiological implications. Low taurine plasma level correlates with prediabetic and diabetic states and taurine supplementation is able to rescue insufficient insulin secretion by pancreatic islets [@pone.0061733-Ribeiro1]. Our data predict that a glucose-dependent up-regulation of the GABA~A~R γ2-subunit in pancreatic islets can reduce taurine action [@pone.0061733-Bailey1] and increase the risk of diabetes. (Patho)physiological correlates of GABA~A~R expression in pancreas await to be determined. Taurine deficiency in the brain results in GABAergic disinhibition, which models pathophysiological conditions of hepatic encephalopathy [@pone.0061733-Sergeeva2]. Thus the disclosure of structural demands for high efficacy taurine gating of GABA~A~R provides the basis for future studies analysing the role of GABA~A~R in diabetes mellitus and hepatic encephalopathy.

Conclusions {#s4a}
-----------

Our study provides new insight into molecular determinants of taurine gating at γ - subunit containing receptors. The mutation of phenylalanine to isoleucine at position 77 in the γ~2~ subunit decreases, whereas introduction of the δ subunit-motif (MTVFLH) increases the efficacy of GABA~A~R gating by taurine. We show, that β~1~ (but not β~3~)-containing receptors display a wide range of taurine efficacies: from superagonism at α~x~β~1~ or α~x~β~1~δ receptors to partial agonism at γ-containing receptors. These findings shed light on the modification of GABA~A~R under (patho)physiological conditions accompanying the loss of endogeneous taurine, such as diabetes mellitus or hepatic encephalopathy.
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**Zinc sensitivity of recombinant GABA~A~ receptors. (A)** Binary (α~x~β~x~, in black) GABA~A~ receptors are inhibited by 1 µM zinc, whereas ternary α~x~β~x~γ~2~ (dark grey) receptors are insensitive to zinc. Delta-containing α~x~β~x~δ receptors (in white) do not differ in zinc-sensitivity from the corresponding α~x~β~x~ receptors. Note that the zinc sensitivity is increased for αβγ~2(δ74--79)~ (light grey) receptors compared to the α~x~β~x~γ~2F77I~ receptors. Values represent mean ± SEM, p values are indicated by asterisk. \* \<0.05, \*\* \<0.01, n.s. = not significant. **(B)** Representative current traces from oocyte recordings. Application is marked by horizontal bars. Scale markers represent 0.1 µA vertically and 20 s horizontally.
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###### 

Click here for additional data file.

###### 

**Tracazolate (10** **µM)-potentiation of GABA-evoked currents is different between ternary δ-containing and corresponding binary α~x~β~x~ GABA~A~R types if GABA at ∼EC~10~ (for the β~1~-) and at ∼EC~99~ (for the β~3~-containing receptors) is used. (A)** When GABA concentration around EC~10~ is used, tracazolate-potentiation of binary α~x~β~1~ (but not α~x~β~3~) receptors is significantly smaller compared to the ternary δ-containing receptors. **(B)** When the same experiments were done at saturating GABA concentrations (∼EC~99~) ternary α~x~β~3~δ-GABA~A~ receptors were potentiated to a larger extent than the corresponding binary receptors. Note no difference between β~1~-containing ternary and binary receptors in experiments with this GABA concentration. p values are indicated by asterisk. \* \<0.05, \*\* \<0.01, \*\*\* \<0.001, n.s. = not significant.
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Click here for additional data file.

###### 

**Zolpidem potentiation of different GABA~A~ receptor types. (A)** Zolpidem modulation of chimeric α~2~β~3~γ~2(δ\ 74--79)~ GABA~A~Rs. Introduction of the δ 74--79 motif MTVFLH into the γ~2~ subunit resulted in loss of potentiation by zolpidem, compared to the WT shown in (B). **(B)** Comparison of zolpidem-potentiation between α~2~β~3~γ~2~, α~2~β~1~γ~2~, α~2~β~1~γ~1~ and α~2~β~3~γ~2F77I~ receptors. Note much larger bi-phasic potentiation by zolpidem at β~3~-containing receptors (in contrast to the β~1~-containing receptors) in accordance with involvement of the low - affinity binding site for BZ at β~3~ but not at β~1~ receptors (44). This site is most likely responsible for the potentiation of GABA -- responses at "zolpidem-resistant" (γ~2F77I~-containing) receptors by 100 µM zolpidem. Data represent mean ± SEM of at least 4 individual oocytes.
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Click here for additional data file.
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